MedPath

Electronic Social Network Assessment Program (eSNAP) + Caregiver Navigator

Not Applicable
Active, not recruiting
Conditions
Brain Cancer
Interventions
Behavioral: eSNAP
Behavioral: Caregiver Navigator
Registration Number
NCT04268979
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Brief Summary

The purpose of the study is to determine if family caregivers of neuro-oncology patients feel less burdened by utilizing the Electronic Social Network Assessment Program (eSNAP) + the Caregiver Navigator.

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
296
Inclusion Criteria
  • English-speaking/reading/writing
  • Able to complete questionnaires (including by proxy)
  • Family Caregivers (FCGs) must self-identify as being a primary FCG of a patient with a primary brain tumor, secondary (metastatic) brain tumor, or leptomeningeal disease diagnosis. A primary caregiver is a family member, friend, or other unpaid person who provides at least some care for a patient at home.
  • Patients must be diagnosed with new or recurrent primary brain tumor, a secondary (metastatic) brain tumor or leptominingeal disease within the last 9 months, receiving at least some evaluation and/or care at Moffitt (i.e. at least one appointment), have a prognosis of at least 9 months
Exclusion Criteria
  • Patients may not participate without a consenting FCG, but FCGs may participate without a consenting patient
  • Patients and FCGs who are experiencing acute distress will be excluded from enrollment and referred directly to social work, per Moffitt policy.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
eSNAP & Caregiver NavigatoreSNAPeSNAP intervention plus questionnaires
eSNAP & Caregiver NavigatorCaregiver NavigatoreSNAP intervention plus questionnaires
Primary Outcome Measures
NameTimeMethod
Family Caregiver Well-Being Using GAD-7 Scale8 weeks per participant

Caregiver well being will be measured using the Generalized Anxiety Disorder 7 Item Scale (GAD-7). The GAD-7 measures anxiety scoring 0-3 points per item, with a total score range 0-21,with a higher score meaning more anxiety.

Neuro Patients Well-Being Using GAD-7 Scale8 weeks per participant

Neuro patients well being will be measured using the Generalized Anxiety Disorder 7 Item Scale (GAD-7). The GAD-7 measures anxiety scoring 0-3 points per item, with a total score range 0-21,with a higher score meaning more anxiety.

Neuro Patients Well-Being using NeuroQol8 weeks per participant

Neuro patients well being will be measured using Neuro-Qol (Neuro Quality of Life) which will be using T scores where the lower values represent worse outcomes.

Family Caregiver Well-Being using PHQ-8 Scale8 weeks per participant

Caregiver well being will be measured using the Personal Health Questionnaire Depression 8 Item Scale Scale (PHQ 8). The PHQ 8 measures depression scoring 0-3 points per item, with a total score range of 0-24, with the higher score meaning more depression.

Neuro Patients Well-Being using PHQ-8 Scale8 weeks per participant

Neuro patients well being will be measured using the Personal Health Questionnaire Depression 8 Item Scale Scale (PHQ 8). The PHQ 8 measures depression scoring 0-3 points per item, with a total score range of 0-24, with the higher score meaning more depression.

Family Caregiver Well-Being Using Zarit Burden Interview8 weeks per participant

Caregiver well being will be measured using the Zarit Burden Interview. The Zarit Burden Interview measures burden scoring 0-4 points per item, with a total score range of 0-48, with the higher score meaning more burden.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Moffitt Cancer Center

đŸ‡ºđŸ‡¸

Tampa, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath